Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 24 von 828
Biochemical and biophysical research communications, 2023-12, Vol.688, p.149214-149214, Article 149214
2023
Volltextzugriff (PDF)

Details

Autor(en) / Beteiligte
Titel
An auristatin-based antibody-drug conjugate targeting EphA2 in pancreatic cancer treatment
Ist Teil von
  • Biochemical and biophysical research communications, 2023-12, Vol.688, p.149214-149214, Article 149214
Ort / Verlag
United States
Erscheinungsjahr
2023
Quelle
MEDLINE
Beschreibungen/Notizen
  • Pancreatic adenocarcinoma, a highly aggressive form of cancer with a poor prognosis, necessitates the development of innovative treatment strategies. Our prior research showcased the growth-inhibiting effects of the anti-EphA2 antibody drug hSD5 on pancreatic cancer tumors. This antibody targets and induces the degradation of the EphA2 receptor while also prompting the antibody's internalization. A deeper dive into the hSD5 Fab crystallographic structure and docking studies revealed that hSD5's CDRH3 drives the primary interaction between hSD5 and the EphA2 active site. In this study, we developed a novel antibody-drug conjugate (ADC)-the auristatin-based hSD5-vedotin specifically targeting EphA2 in pancreatic cancer cells. This ADC aims at the tumor-specific antigen EphA2, triggering endocytosis and releasing the conjugated payload molecule Monomethyl auristatin E (MMAE), amplifying the tumor-killing effect. Upon cellular entry, hSD5-vedotin demonstrated an impressive tumor-killing response, inhibiting tumor cell growth and promoting apoptosis even at lower antibody concentrations. In a pancreatic cancer xenograft animal model, hSD5-vedotin showcased the potential to suppress tumor growth entirely. Notably, potential immune resistance responses were also observed in recurrent pancreatic cancer tumors. Our empirical results underscore the possibility of developing hSD5-vedotin further, which we anticipate will have a broader and more potent therapeutic impact on pancreatic cancer and other EphA2-related cancers.
Sprache
Englisch
Identifikatoren
ISSN: 0006-291X
eISSN: 1090-2104
DOI: 10.1016/j.bbrc.2023.149214
Titel-ID: cdi_proquest_miscellaneous_2889241383

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX